While antibodies are set to be increasingly important as therapeutic options for cancer and other diseases, the discovery of fully functional antibodies that lack light chains in Camelidae (camels and llamas) has opened the door to an exciting new generation of therapeutic antibodies known as nanobodies.
Unlike conventional antibodies, the heavy-chain antibodies of Camelidae contain a single variable domain (VHH) and two constant domains (CH2 and CH3) only. Using these functional antibodies as a base, nanobodies – small, single-domain antibody fragments that retain full antigen-binding capabilities and the properties of heavy-chain antibodies – have been created.
In this expert webinar, Pieter Kennis, Associate Scientist for the high-throughput profiling unit at Ablynx, discusses these proteins. Through multiplexing of primary screening assays and semi-automated dose response binding data analysis, we explore antibody binding using the Intellicyt® iQue Screener to accelerate lead identification.
Watch this expert webinar to learn about:
The live webinar will take place on Tuesday, June 11, 2019, at:
Scheduling conflict? Register to receive an on-demand link to watch later>>